ES2183815T3 - Quimioterapia para el cancer. - Google Patents
Quimioterapia para el cancer.Info
- Publication number
- ES2183815T3 ES2183815T3 ES93918397T ES93918397T ES2183815T3 ES 2183815 T3 ES2183815 T3 ES 2183815T3 ES 93918397 T ES93918397 T ES 93918397T ES 93918397 T ES93918397 T ES 93918397T ES 2183815 T3 ES2183815 T3 ES 2183815T3
- Authority
- ES
- Spain
- Prior art keywords
- fatty acid
- fas
- cells
- acid synthesis
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Abstract
LA SINTESIS DE ACIDOS GRASOS (FAS) ESTA SOBRE-EXPRESADA EN CARCINOMAS CON PRONOSTICO POBRE, PERO POCO DE LA EXPRESION FAS SE IDENTIFICA CON TEJIDOS NORMALES. LA INHIBICION DE LA SINTESIS DE ACIDOS GRASOS ES SELECTIVAMENTE TOXICA PARA CELULAS DE CARCINOMA, MIENTRAS LAS CELULAS NORMALES CON UNA ACTIVIDAD FAS PEQUEÑA SON RESISTENTES. ESTA INVENCION PROPORCIONA UN METODO DE TRATAMIENTO PARA LOS PACIENTES DE CANCER DONDE LA SINTESIS DE ACIDOS GRASOS POR CELULAS DE LOS TUMORES DE PACIENTES SE INHIBEN CON LA RESULTANTE INTERRUPCION DEL PROCESO DE LA ENFERMEDAD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91771692A | 1992-07-24 | 1992-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2183815T3 true ES2183815T3 (es) | 2003-04-01 |
Family
ID=25439227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93918397T Expired - Lifetime ES2183815T3 (es) | 1992-07-24 | 1993-07-26 | Quimioterapia para el cancer. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0651636B1 (es) |
JP (1) | JPH07509470A (es) |
KR (2) | KR100325766B1 (es) |
AT (1) | ATE225167T1 (es) |
AU (1) | AU682007B2 (es) |
CA (1) | CA2140866C (es) |
DE (1) | DE69332353T2 (es) |
DK (1) | DK0651636T3 (es) |
ES (1) | ES2183815T3 (es) |
MX (1) | MX9304501A (es) |
PT (1) | PT651636E (es) |
WO (1) | WO1994002108A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614551A (en) * | 1994-01-24 | 1997-03-25 | The Johns Hopkins University | Inhibitors of fatty acid synthesis as antimicrobial agents |
US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
ES2251002T3 (es) * | 1995-11-17 | 2006-04-16 | The Johns Hopkins University | Inhibicion de sintasa de acido graso, como medio para reducir la masa adipocita. |
PT1621077E (pt) | 1997-10-15 | 2008-11-04 | Polarx Biopharmaceuticals Inc | Composições farmacêuticas compreendendo trióxido de arsénico para o tratamento de um tumor do sistema nervoso central |
DK2255800T3 (da) | 1997-11-10 | 2013-02-04 | Sloan Kettering Inst Cancer | Arsentrioxid til anvendelse ved behandling af leukæmi |
CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
WO2001034145A1 (en) * | 1999-11-12 | 2001-05-17 | The Johns Hopkins University School Of Medicine | Treating cancer by increasing intracellular malonyl coa levels |
CA2417500C (en) | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
US20020173447A1 (en) * | 2001-02-15 | 2002-11-21 | Pizer Ellen Sarah | Cytostatic effects of fatty acid synthase inhibition |
US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7354928B2 (en) | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
JP2006507306A (ja) * | 2002-10-31 | 2006-03-02 | ファスゲン,インク. | 脂肪酸シンターゼ阻害剤による癌の発生を阻害する方法 |
WO2004100885A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
CA2561303C (en) | 2004-03-25 | 2011-01-18 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
AU2005274165A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
EP2018873A4 (en) * | 2006-04-07 | 2009-12-09 | Japan Found Cancer | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER |
US8729239B2 (en) | 2009-04-09 | 2014-05-20 | Nuclea Biotechnologies, Inc. | Antibodies against fatty acid synthase |
WO2014183047A1 (en) | 2013-05-10 | 2014-11-13 | Memorial Sloan Kettering Cancer Center | Lipid scavenging in ras cancers |
KR102136643B1 (ko) | 2018-12-04 | 2020-07-22 | 재단법인대구경북과학기술원 | 신규한 간암 진단 마커 및 이의 용도 |
TW202133727A (zh) * | 2019-11-25 | 2021-09-16 | 日商花王股份有限公司 | 分枝脂肪酸之代謝控制方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328246A (en) * | 1979-08-14 | 1982-05-04 | Joseph Gold | Anti Walker 256 carcinoma agent and combination thereof |
JPS59225115A (ja) * | 1983-06-06 | 1984-12-18 | Ota Seiyaku Kk | 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル |
JPS6058917A (ja) * | 1983-09-09 | 1985-04-05 | Rikagaku Kenkyusho | 制癌剤 |
GB8607137D0 (en) * | 1986-03-21 | 1986-04-30 | Efamol Ltd | Compositions |
DD252616B1 (de) * | 1986-09-08 | 1990-06-20 | Adw Ddr | Verfahren zur herstellung von cerulenin auf mikrobiologischem wege |
JPH01132542A (ja) * | 1987-11-19 | 1989-05-25 | Toomen:Kk | ゴッシポールラセミ体の光学分割法 |
JPH02113850A (ja) * | 1988-10-21 | 1990-04-26 | Nippon Oil & Fats Co Ltd | 発癌抑制用油脂組成物 |
JPH02247125A (ja) * | 1989-03-17 | 1990-10-02 | Koken Kk | 悪性腫瘍細胞増殖抑制剤 |
-
1993
- 1993-07-26 KR KR1019950700317A patent/KR100325766B1/ko not_active IP Right Cessation
- 1993-07-26 KR KR1020017009035A patent/KR100329245B1/ko not_active IP Right Cessation
- 1993-07-26 DK DK93918397T patent/DK0651636T3/da active
- 1993-07-26 AT AT93918397T patent/ATE225167T1/de not_active IP Right Cessation
- 1993-07-26 JP JP6504755A patent/JPH07509470A/ja active Pending
- 1993-07-26 WO PCT/US1993/007023 patent/WO1994002108A1/en active IP Right Grant
- 1993-07-26 CA CA002140866A patent/CA2140866C/en not_active Expired - Fee Related
- 1993-07-26 ES ES93918397T patent/ES2183815T3/es not_active Expired - Lifetime
- 1993-07-26 EP EP93918397A patent/EP0651636B1/en not_active Expired - Lifetime
- 1993-07-26 AU AU47864/93A patent/AU682007B2/en not_active Ceased
- 1993-07-26 DE DE69332353T patent/DE69332353T2/de not_active Expired - Fee Related
- 1993-07-26 PT PT93918397T patent/PT651636E/pt unknown
- 1993-07-26 MX MX9304501A patent/MX9304501A/es not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT651636E (pt) | 2003-02-28 |
JPH07509470A (ja) | 1995-10-19 |
DK0651636T3 (da) | 2003-01-27 |
CA2140866C (en) | 2003-05-27 |
KR100325766B1 (ko) | 2002-07-27 |
AU682007B2 (en) | 1997-09-18 |
DE69332353T2 (de) | 2003-07-10 |
KR100329245B1 (ko) | 2002-03-18 |
ATE225167T1 (de) | 2002-10-15 |
CA2140866A1 (en) | 1994-02-03 |
DE69332353D1 (de) | 2002-11-07 |
EP0651636A1 (en) | 1995-05-10 |
WO1994002108A1 (en) | 1994-02-03 |
MX9304501A (es) | 1994-04-29 |
AU4786493A (en) | 1994-02-14 |
EP0651636B1 (en) | 2002-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2183815T3 (es) | Quimioterapia para el cancer. | |
Vonderheid et al. | A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy | |
DK0738107T3 (da) | Inhibitorer for fedtsyresyntese som antimikrobielle midler | |
HUP0000558A2 (hu) | Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
BG103152A (en) | Appoptosis-inducing adamantyl derivatives and their application as anticarcerogenic forms | |
MX9804009A (es) | Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. | |
AU1195499A (en) | Thyroxine analogues having no significant hormonal activity to treat malignant tumors | |
IL127384A0 (en) | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity | |
JP2714402B2 (ja) | 癌転移抑制剤 | |
Poen et al. | Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil | |
BRPI0414736A (pt) | 5-aril-pirimidinas como agentes anticáncer | |
WO2002039999B1 (en) | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition | |
ATE406160T1 (de) | Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs | |
BR9808263A (pt) | Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto. | |
WILLETT et al. | Adjuvant postoperative radiation therapy for colonic carcinoma | |
Lehnert et al. | Effect of flurbiprofen and 16, 16-dimethyl prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in rats: Glandular epithelium of stomach and duodenum | |
US5525626A (en) | Treating susceptible human malignant tumors with 7-hydroxy-1,2-benzopyrone | |
Handley | Indications and Contraindications | |
RU2000101293A (ru) | Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы | |
CN114767692A (zh) | 一种去甲泽拉木醛和二甲双胍的联合用药物 | |
KR920700636A (ko) | 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도 | |
JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
Kröger et al. | 361 Dexverapamil to overcome anthracycline-resistance in advanced breast cancer | |
Schipper et al. | Polyamine metabolism and programmed cell death in prostatic cancer cells |